Fig. 4From: 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPDChange from baseline in average daily rescue medication use over 4-week treatment period. Data shown are ± SE for mITT population in (a) PT003011 and (b) PT003012. GFF, glycopyrrolate/formoterol fumarate; LSM, least squares means; MDI, metered dose inhaler; mITT, modified intent-to-treat; SE, standard error; SMI, Soft Mist™ inhalerBack to article page